Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Vifor Fresenius Medical Care Renal Pharman = 26018 May 2023 to 25 Sept 2024
Uremic Pruritus
PepBank has 41 difelikefalin studies with results. 40 of them gave difelikefalin, with 272 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 272 results and 71 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Difelikefalin is a synthetic peptide kappa opioid receptor agonist. Its label concerns CKD-associated pruritus in adults receiving hemodialysis.
| Target | Action | Evidence |
|---|---|---|
| Kappa opioid receptorOPRK1P41145 (opens in a new tab) | Agonist | Official prescribing information, mechanism of actionSource (opens in a new tab) |
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
5 amino acids · 5 modifications
Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
No charge curve
The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.
5 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 24794466(opens in a new tab)
CC(C)C[C@H](C(=O)N[C@H](CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CC3=CC=CC=C3)NPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
41 of 71 studies have results (58%), published 2020 to 2026. Top row: every study. Bottom row: studies with results about Difelikefalin, by class. The rows use different scales.
Studies71 in all, 2020 to 2026
Studies with results41 in all, 2020 to 2026
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
28 trials match. Highest phase first. Data from ClinicalTrials.gov.
25 of 28 trials
Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
NCT00877799Mar 2009 to Jan 2010
Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery
NCT01361568Jul 2011 to Apr 2012
A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery
NCT01789476May 2013 to Aug 2013
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
NCT02229929Jul 2014 to Jul 2015
A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
NCT02524197Aug 2015 to Jan 2016
A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery
NCT02542384Sept 2015 to Jun 2018
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
NCT02858726Jun 2016 to 14 Mar 2017
A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee
NCT02944448Sept 2016 to Jun 2017
Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
NCT0328153814 Aug 2017 to 11 Feb 2020
A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)
NCT0342265320 Feb 2018 to 26 Mar 2020
25 trials · 1 ongoing · 19 completed · 5 stopped early · 12 with posted results · source ClinicalTrials.gov (opens in a new tab)
Vifor Fresenius Medical Care Renal Pharman = 26018 May 2023 to 25 Sept 2024
Uremic Pruritus
Cara Therapeutics, Inc.n = 2141 Aug 2023 to 7 May 2024
Pruritus · Notalgia Paresthetica
Cara Therapeutics, Inc.n = 28617 May 2022 to 29 Feb 2024
Chronic Kidney Diseases · Pruritus
Cara Therapeutics, Inc.n = 10526 Aug 2022 to 26 Feb 2024
Chronic Kidney Diseases · Pruritus
Cara Therapeutics, Inc.n = 28716 Aug 2022 to 2 Feb 2024
Pruritus · Atopic Dermatitis
Cara Therapeutics, Inc.n = 37820 Feb 2018 to 26 Mar 2020
Uremic Pruritus
Cara Therapeutics, Inc.n = 47317 Jul 2018 to 30 Mar 2020
Uremic Pruritus
Cara Therapeutics, Inc.n = 2226 May 2019 to 6 Mar 2020
Uremic Pruritus
Cara Therapeutics, Inc.n = 28814 Aug 2017 to 11 Feb 2020
Uremic Pruritus
Cara Therapeutics, Inc.n = 226Jun 2016 to 14 Mar 2017
Uremic Pruritus
Cara Therapeutics, Inc.n = 451Sept 2015 to Jun 2018
Post Abdominal Surgery Pain
Vifor Fresenius Medical Care Renal Pharman = 184 Aug 2026 to est. 15 Aug 2029
Pruritus · Chronic Kidney Diseases
Cara Therapeutics, Inc.n = 2695 Jul 2018 to 14 Nov 2019
Chronic Kidney Diseases · Pruritus
Cara Therapeutics, Inc.n = 1425 Jun 2019 to 29 Jun 2022
Cholestatic Pruritus
Cara Therapeutics, Inc.n = 12611 Jan 2021 to 30 Jun 2022
Pruritus · Notalgia Paresthetica
Cara Therapeutics, Inc.n = 40129 Jun 2019 to 1 Apr 2021
Pruritus · Atopic Dermatitis
Cara Therapeutics, Inc.n = 761Sept 2016 to Jun 2017
Osteoarthritis, Hip · Osteoarthritis, Knee · Arthritis · Joint Diseases · Musculoskeletal Diseases · Rheumatic Diseases
Cara Therapeutics, Inc.n = 81Aug 2015 to Jan 2016
Osteoarthritis
Cara Therapeutics, Inc.n = 89Jul 2014 to Jul 2015
Pruritus · Uremic Pruritus
Cara Therapeutics, Inc.n = 114Mar 2009 to Jan 2010
Acute Pain
Cara Therapeutics, Inc.n = 51May 2013 to Aug 2013
Acute Pain
Cara Therapeutics, Inc.n = 203Jul 2011 to Apr 2012
Postoperative Pain
Vifor Fresenius Medical Care Renal Pharman = 3026 Jun 2023 to 9 Oct 2023
End Stage Renal Disease on Hemodialysis
Cara Therapeutics, Inc.n = 3531 Dec 2019 to 11 Jun 2020
Hemodialysis
Cara Therapeutics, Inc.n = 5720 Jun 2019 to 29 Oct 2019
Healthy
Studies on this peptide. Some have results. The others have none yet.
71 studies match. Retracted studies are left out.
Showing 25 of 71 studiesquery qry_1fbb5e6784750096075dd5df
41 studies in all, 19 on this page
Randomized controlled trial · 2020
Fishbane et al. 2020The New England journal of medicinen = 323cited by 267
PMID 31702883DOI 10.1056/nejmoa1912770PUB-31702883
Randomized controlled trial · 2020
Fishbane et al. 2020Kidney international reportsn = 174cited by 75
PMID 32405581PMC7210745DOI 10.1016/j.ekir.2020.01.006PUB-32405581
Randomized controlled trial · 2022
Topf et al. 2022Kidney medicinen = 851cited by 67
PMID 36016762PMC9396406DOI 10.1016/j.xkme.2022.100512PUB-36016762
Randomized controlled trial · 2022
Fishbane et al. 2022Kidney medicinen = 1,306cited by 38
PMID 36039153PMC9418597DOI 10.1016/j.xkme.2022.100513PUB-36039153
Randomized controlled trial · 2022
Narita et al. 2022JAMA network opencited by 31
PMID 35511180PMC9073569DOI 10.1001/jamanetworkopen.2022.10339PUB-35511180
Randomized controlled trial · 2021
Viscusi et al. 2021Clinical and translational sciencen = 15cited by 26
PMID 33982405PMC8504812DOI 10.1111/cts.13042PUB-33982405
Randomized controlled trial · 2023
Kim et al. 2023The New England journal of medicinecited by 25
PMID 36780675DOI 10.1056/nejmoa2210699PUB-36780675
Randomized controlled trial · 2023
Yosipovitch et al. 2023Journal of the American Academy of Dermatologycited by 25
PMID 37059302DOI 10.1016/j.jaad.2023.03.051PUB-37059302
Randomized controlled trial · 2022
Shram et al. 2022Clinical and translational sciencen = 44cited by 24
PMID 34708917PMC8841457DOI 10.1111/cts.13173PUB-34708917
Non-randomized trial · 2023
Guttman-Yassky et al. 2023The Journal of allergy and clinical immunologyn = 401cited by 19
PMID 37453614DOI 10.1016/j.jaci.2023.06.023PUB-37453614
Non-randomized trial · 2022
Weiner et al. 2022Kidney medicinen = 222cited by 17
PMID 36185706PMC9516453DOI 10.1016/j.xkme.2022.100542PUB-36185706
Animal study (in vivo) · mouse · 2023
Tamari et al. 2023The Journal of allergy and clinical immunologycited by 13
PMID 37453613DOI 10.1016/j.jaci.2023.06.022PUB-37453613
Observational study · 2024
Weiner et al. 2024Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Associationcited by 13
PMID 37968132PMC11210984DOI 10.1093/ndt/gfad245PUB-37968132
Non-randomized trial · 2024
Fotheringham et al. 2024The patientn = 197cited by 12
PMID 38196014PMC10894140DOI 10.1007/s40271-023-00668-1PUB-38196014
Animal study (in vivo) · rat · 2022
Meariman et al. 2022Pharmacological researchcited by 9
PMID 36202183DOI 10.1016/j.phrs.2022.106470PUB-36202183
Non-randomized trial · 2023
Stark et al. 2023Clinical pharmacokineticsn = 12cited by 9
PMID 37369955PMC10450003DOI 10.1007/s40262-023-01262-2PUB-37369955
Randomized controlled trial · 2023
Spencer et al. 2023Clinical and translational sciencen = 30cited by 8
PMID 37128642PMC10499405DOI 10.1111/cts.13538PUB-37128642
Randomized controlled trial · 2023
Narita et al. 2023NEJM evidencen = 178cited by 6
PMID 38320524DOI 10.1056/evidoa2300094PUB-38320524
Randomized controlled trial · 2026
Spencer et al. 2026The Journal of investigative dermatologycited by 6
PMID 40409676DOI 10.1016/j.jid.2025.04.035PUB-40409676
30 studies in all, 6 on this page
Indexing hint: Animal study · 2021
Inan et al. 2021Molecules (Basel, Switzerland)cited by 18
PMID 34576988PMC8466557DOI 10.3390/molecules26185517PUB-34576988
PubMed tag: none · 2022
Elmariah et al. 2022JAAD internationalcited by 15
PMID 35497636PMC9046882DOI 10.1016/j.jdin.2022.03.007PUB-35497636
PubMed tag: none · 2023
Beck et al. 2023Itch (Philadelphia, Pa.)cited by 12
PMID 38099236PMC10720604DOI 10.1097/itx.0000000000000072PUB-38099236
PubMed tag: none · 2022
Chen et al. 2022Frontiers in pharmacologycited by 9
PMID 35652052PMC9149264DOI 10.3389/fphar.2022.835809PUB-35652052
PubMed tag: none · 2023
Thokala et al. 2023PharmacoEconomicscited by 9
PMID 36735201PMC10020261DOI 10.1007/s40273-022-01237-4PUB-36735201
PubMed tag: Practice Guideline · 2024
Manuel Buades et al. 2024Nefrologiacited by 5
PMID 39034226DOI 10.1016/j.nefroe.2024.07.003PUB-39034226
Page 1 of 1
Fishbane S · The New England journal of medicine · 2020
Randomized controlled trial · 8 results
Narita I · NEJM evidence · 2023
Randomized controlled trial · 4 results
Fishbane S · Kidney international reports · 2020
Randomized controlled trial · 10 results
Shram MJ · Clinical and translational science · 2022
Randomized controlled trial · 14 results
Spencer RH · Clinical and translational science · 2023
Randomized controlled trial · 4 results
Viscusi ER · Clinical and translational science · 2021
Randomized controlled trial · 12 results
Narita I · JAMA network open · 2022
Randomized controlled trial · 11 results
Yosipovitch G · Journal of the American Academy of Dermatology · 2023
Randomized controlled trial · 14 results
Kim BS · The New England journal of medicine · 2023
Randomized controlled trial · 6 results
Zuo L · Clinical kidney journal · 2026
Randomized controlled trial · 5 results
Fishbane S · American journal of nephrology · 2024
Randomized controlled trial · 5 results
Fishbane S · Kidney medicine · 2022
Randomized controlled trial · 14 results
Topf J · Kidney medicine · 2022
Randomized controlled trial · 6 results
Spencer RH · The Journal of investigative dermatology · 2026
Randomized controlled trial · 3 results
Weiner DE · Kidney medicine · 2022
Non-randomized trial · 11 results
McCafferty K · Journal of renal care · 2025
Non-randomized trial · 10 results
Burton JO · Kidney & blood pressure research · 2026
Non-randomized trial · 6 results
Guttman-Yassky E · The Journal of allergy and clinical immunology · 2023
Non-randomized trial · 12 results
Fotheringham J · The patient · 2024
Non-randomized trial · 7 results
Spencer RH · BMC nephrology · 2024
Non-randomized trial · 10 results
Stark JG · Clinical pharmacokinetics · 2023
Non-randomized trial · 10 results
Mourani C · Pediatric nephrology (Berlin, Germany) · 2026
Non-randomized trial · 8 results
Ständer S · Clinical kidney journal · 2024
Non-randomized trial · 6 results
Brasme R · Nephrologie & therapeutique · 2024
Observational study · 4 results
Latus J · Clinical kidney journal · 2025
Observational study · 7 results
Di Giovanni M · International urology and nephrology · 2026
Observational study · 11 results
Aucella F · Clinical kidney journal · 2025
Observational study · 8 results
Naar L · Journal of patient-reported outcomes · 2026
Observational study · 1 result
Weiner DE · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
Observational study · 1 result
Zhao J · Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
Observational study · 11 results
Mima Y · Cureus · 2025
Case report or series · 2 results
Werzowa JM · Case reports in nephrology · 2025
Case report or series · 3 results
Li KC · Kidney medicine · 2026
Case report or series · 1 result
Larsen GØ · Ugeskrift for laeger · 2025
Case report or series · 4 results
Tamari M · The Journal of allergy and clinical immunology · 2023
Animal study (in vivo) · mouse · 3 results
Meariman JK · Pharmacological research · 2022
Animal study (in vivo) · rat · 5 results
Ming C · Journal of pharmaceutical sciences · 2026
Animal study (in vivo) · rat · 12 results
Sawanobori Y · PloS one · 2026
Animal study (in vivo) · mouse · 7 results
Takeuchi H · BMC nephrology · 2025
Animal study (in vivo) · rat · 5 results
Xu X · Small (Weinheim an der Bergstrasse, Germany) · 2026
Other design · 2 results
Zhang H · Nature communications · 2026
Not a test of Difelikefalin alone · 1 result
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA |
| 27 Oct 2026 | dailymed.nlm.nih.gov (opens in a new tab) |
| EU | EMA |
| 27 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Not listed as banned by WADA Difelikefalin is not named in the 2026 list, including S7 narcotics. | 2026 List | wada-ama.org (opens in a new tab) |
123 safety results for Difelikefalin.
In hemodialysis patients, diarrhea occurred in 9.0% with difelikefalin versus 5.7% with placebo.
Randomized controlled trialn = 848
In Black/AA patients, treatment-emergent adverse events occurred in 78.5% with difelikefalin versus 70.8% with placebo.
Randomized controlled trialn = 249
In hemodialysis patients, treatment-related adverse events occurred in 13 of 89 difelikefalin recipients (15%) versus 3 of 89 placebo recipients (3%).
Randomized controlled trialn = 178
1 more measurement in the study.
In recreational polydrug users, difelikefalin produced significantly lower peak Drug Liking VAS scores than pentazocine.
Randomized controlled trialn = 44
In hemodialysis patients, withdrawal scores were similar after stopping or continuing difelikefalin, with a placebo-minus-difelikefalin difference of 0.52 (95% CI -0.56, 1.59).
Randomized controlled trialn = 30
In healthy volunteers, neither difelikefalin nor placebo met the respiratory-depression criterion: ETCO2 rise ≥10 mm Hg versus baseline or ETCO2 >50 mm Hg sustained ≥30 seconds.
Randomized controlled trialn = 15
In hemodialysis patients, diarrhea was more common with difelikefalin than placebo.
Randomized controlled trialn not reported
In hemodialysis patients, treatment-emergent adverse events occurred in 78% with difelikefalin versus 42% with placebo.
Randomized controlled trialn not reported
The top 24 of 123 results.
The doses that these studies used. They are not recommendations.
0.5 μg/kg three times per weekHuman
0.5 μg/kg three times per weekHuman
0.5, 1.0, or 1.5 μg/kg thrice weeklyHuman
5 and 15 mcg/kgHuman
1.0 and 5.0 mcg/kgHuman
0.25 μg/kg three times a weekHuman
6 of 33 shown
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https:// pepbank.io/ v1/ briefs/ difelikefalinEvidence summary for Difelikefalin: counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 8 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Adverse eventsWhole body | Human: 103 results from 24 studies: 31 increase, 5 decrease, 15 no significant change, 52 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 103 |
| Skin and hairSkin and wound | Human: 56 results from 18 studies: 11 increase, 27 decrease, 3 no significant change, 15 not reported. Strongest design: Randomized controlled trial | Animal: 2 results from 2 studies: 2 decrease. Strongest design: Animal study (in vivo) | Lab: 1 result from 1 study: 1 decrease. Strongest design: Other design | No results | 59 |
| PharmacokineticsPharmacology | Human: 23 results from 3 studies: 6 increase, 1 decrease, 16 not reported. Strongest design: Non-randomized trial | Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo) | No results | No results | 24 |
| Quality of lifeWhole body | Human: 19 results from 9 studies: 4 increase, 1 decrease, 2 no significant change, 12 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 19 |
| Gastrointestinal adverse eventsGastrointestinal | Human: 13 results from 8 studies: 5 increase, 8 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 13 |
| PruritusSkin and wound | Human: 10 results from 4 studies: 6 increase, 2 decrease, 2 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 10 |
| SleepSleep | Human: 9 results from 8 studies: 1 increase, 3 decrease, 5 not reported. Strongest design: Randomized controlled trial | No results | No results | No results | 9 |
| MortalityWhole body | Human: 6 results from 6 studies: 1 decrease, 5 not reported. Strongest design: Randomized controlled trial | Animal: 1 result from 1 study: 1 decrease. Strongest design: Animal study (in vivo) | No results | No results | 7 |
| Inflammation markersSkin and wound | Human: 4 results from 2 studies: 3 decrease, 1 no significant change. Strongest design: Randomized controlled trial | Animal: 3 results from 3 studies: 1 decrease, 2 no significant change. Strongest design: Animal study (in vivo) | Lab: 1 result from 1 study: 1 decrease. Strongest design: In vitro (cells) | No results | 8 |
| Receptor activity and mechanismSkin and wound | Human: 2 results from 1 study: 2 decrease. Strongest design: Non-randomized trial | No results | Lab: 1 result from 1 study: 1 not reported. Strongest design: In vitro (cells) | Computer model: 1 result from 1 study: 1 decrease. Strongest design: In silico | 4 |
| Treatment adherence and retentionWhole body | Human: 2 results from 1 study: 2 not reported. Strongest design: Observational study | No results | No results | No results | 2 |
| Kidney functionKidney and urinary | No results | Animal: 12 results from 3 studies: 3 increase, 9 decrease. Strongest design: Animal study (in vivo) | No results | No results | 12 |
12 outcome groups shown of 14 · 272 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.
Trials by phase
25 registered trials loaded of 28, grouped by phase and shown by status.
Source: ClinicalTrials.gov, data version 308560. Status is the registry status. The counts cover only the loaded trials.